Every 10-Q that Immucell Corp (ICCC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ICCC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ICCC filings page.
ImmuCell Corporation reported strong growth for the three and six months ended June 30, 2026, driven by its First Defense® calf health products. Product sales for the first half rose to $17.5 million, up 20.9% year over year, with domestic revenue increasing and international sales declining.
Net income for the first half increased to $3.8 million from $1.9 million, helped by a $2.0 million settlement with a former contract manufacturer and lower Re-Tain® development spending after the decision to cease seeking FDA approval. Gross profit improved in dollars but margin compressed as costs of goods sold grew faster than sales, reflecting higher raw material costs, manufacturing inefficiencies and the reclassification of Re-Tain® facility costs into production.
Operating cash flow strengthened to $6.6 million, boosting cash and equivalents to $8.9 million while debt declined modestly to about $8.3 million. The company is reallocating its former Re-Tain® facility to expand First Defense® capacity, planning roughly $8.0 million of related investments over 12–18 months, and remains highly dependent on two major customers and colostrum supply.
ImmuCell Corporation reported strong first-quarter 2026 growth, with higher sales and profitability. Product sales reached $10.36 million, up 28.4% from $8.07 million a year earlier, driven mainly by higher volumes and price increases in its First Defense® line. Net income rose to $1.94 million from $1.45 million, and basic and diluted earnings per share increased to $0.21 from $0.16. Gross profit improved to $4.66 million as cost of goods sold grew more slowly than revenue, helped by price actions and manufacturing efficiencies. Operating cash flow more than doubled to $3.57 million, boosting cash and cash equivalents to $6.81 million while total debt edged down to $8.70 million. The company also changed useful-life estimates on certain idle Re-Tain® assets, reducing quarterly depreciation by about $0.1 million. After quarter-end, ImmuCell entered a Settlement Deed under which Norbrook Laboratories agreed to pay $2.0 million, resolving a prior development and supply agreement.
ImmuCell Corporation (ICCC) reported Q3 2025 results. Product sales were $5,506,122 versus $6,011,573 a year ago, and the quarter showed a net loss of $139,748 compared with a loss of $701,690 last year. Gross margin improved to $2,363,098 from $1,583,554 as costs of goods sold declined.
For the nine months ended September 30, 2025, product sales reached $20,018,175 versus $18,742,040, and net income was $1,809,115 versus a loss of $2,671,184 last year. Cash and cash equivalents were $3,886,198. Inventory stood at $9,802,005. Total liabilities were $15,929,282 and stockholders’ equity was $29,800,841.
Capital and financing: During Q3 2025, the company refinanced prior loans into a new $2,327,119 MCB term loan at a fixed 6.5% rate, replacing 7% and 8% debt, removing July 2026 balloon payments and setting monthly payments of $45,637 through the third quarter of 2030.
Concentration: Two customers represented 68% of Q3 product sales. Shares outstanding were 9,045,851 as of October 31, 2025.